Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication CIPRO is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: • Skin and Skin Structure Infections ( 1.1 ) • Bone and Joint Infections ( 1.2 ) • Complicated Intra-Abdominal Infections ( 1.3 ) • Infectious Diarrhea ( 1.4 ) • Typhoid Fever (Enteric Fever) ( 1.5 ) •…
Cipro · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cipro XR (Ciprofloxacin, BAYQ3939) | DRUG | Ciprofloxacin XR 1000 mg orally once a day |
| Cipro IR (Ciprofloxacin, BAYQ3939) | DRUG | Ciprofloxacin IR 500 mg orally twice a day |
Inclusion Criteria: The primary diagnosis in this clinical trial was cUTI in men or non-pregnant women over 18 years of age. Other main inclusion criteria: * One or more clinical symptoms and signs of a lower UTI: fever (\> 38°C, orally), chills, frequency of micturition, dysuria, urge sensation. ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Gepotidacin, UTI vaccine candidate |
| CorMedix Inc. | CRMD | 1 | PHASE2 | Meropenem-Vaborbactam |
Cipro is used for urinary tract infections. It is a small molecule anti-infective developed by Bayer AG. A Phase 3 trial evaluated its use in patients with complicated urinary tract infections, comparing CIPRO XR with CIPRO IR. Cipro is also known as Cipro XR, ciprofloxacin, or BAYQ3939.
Cipro is made by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer developed and studied the drug, including a Phase 3 trial in complicated urinary tract infections. Cipro is also known by the names Cipro XR, ciprofloxacin, and BAYQ3939.
Cipro has been studied in Phase 3 clinical development. One Phase 3 trial has been completed, and no trials are currently active. The completed trial enrolled 212 patients with complicated urinary tract infections and compared CIPRO XR with CIPRO IR.
Cipro has been studied in one completed Phase 3 trial, NCT00668122, titled "Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections." The trial enrolled 212 patients in Italy, was randomized, double-blind, and controlled, and included adults 18 years and older.
Yes, Cipro XR is an alternative name for Cipro. The drug is also known as ciprofloxacin or BAYQ3939. Cipro XR was compared with CIPRO IR in a Phase 3 trial for complicated urinary tract infections. All these names refer to the same active ingredient, ciprofloxacin.